Metastatic breast cancer appears months or years later when a person has stopped receiving treatment for breast cancer, such as stage I, II, or III. Therefore, distant recurrence is another name for metastatic breast cancer. Over 168,000 women in the US had metastatic breast cancer as of 2020.

The market for metastatic breast cancer treatments was USD 17.13 billion in 2021 and will reach $41.74 billion by 2030 at a 10.4% CAGR during the forecast period.

Chemotherapy & radiation therapy are the most frequently recommended therapies for metastatic breast cancer. Both of these therapies help in reducing tumor growth. Hormone therapy is the most effective treatment as it aids in slowing the spread of cancer cells. Major factors propelling the global market’s growth are the metastatic breast cancer treatment industry trends, which include the introduction of more cutting-edge technologies and increased demand for metastatic breast cancer medicines.

Market Dynamics

Drivers

Workplace stress has risen as a result of the quick business culture, with work-from-home following COVID-19 fueling the flames. Furthermore, people’s sedentary lives have contributed to a variety of health issues. Because of these causes, the prevalence of breast cancer has increased, which will expand the market for breast cancer therapy. Breast cancer rates have increased as a result of a lack of exercise, an overly stressful daily routine, and a refusal to acknowledge health difficulties. According to SUSAN G. KOMEN, more than 287,000 new invasive breast cancer cases in women and 2,700 cases in men are likely to be discovered in the United States in 2022, with nearly 44,000 women and men expected to die from the disease.

Restraints

A lack of efficient medicines and side effects from such treatments may constrain the market for treating metastatic breast cancer. The market expansion is hampered by the high cost of treating metastatic breast cancer.

Opportunity 

In the next years, higher investments in R&D and growing cancer diagnostics awareness campaigns will help this market expand significantly. Furthermore, the industry will grow as a result of considerable improvements in reimbursement rules. The Asia-Pacific market is anticipated to develop at the quickest rate because of the large patient pool, government efforts, and government funding to discover novel medications and improve healthcare conditions.

Market Segmentation 

Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, and Hormone Therapy are several treatments that make up the overall market. Chemotherapy accounted for around 28.8% of the market for treatments for metastatic breast cancer, which was the largest share of any of these segments. Since chemotherapy slows the entire process of the tumor’s growth, it is the most often used treatment for metastatic breast cancer. In 2018, roughly 9.8 million patients needed first-line chemotherapy, and by the end of 2040, that number will rise to 15 million.

Hospitals, Clinics, and Others comprise the three segments of the overall market based on end-users. The hospital market segment held the greatest global market share for treating metastatic breast cancer among all market sectors. The hospital segment currently dominates the global market and is expected to maintain its dominance for the duration of the forecasted period due to the rising number of hospitals in developing nations and the widespread availability of various medical treatment equipment and pharmaceuticals.

Regional Insights

In 2020, North America had the highest market share of nearly 46.72%. It is mainly because of the increase in healthcare spending, which well-known healthcare service providers, and the rising incidence of cancer throughout the entire region support. Additionally, North American nations like the United States, Canada, and Mexico are spending money on promoting breast cancer awareness campaigns, which is expected to support the expansion of the regional market. Additionally, as cancer cases increase, there will likely be an exponential increase in the requirement for metastatic breast cancer therapy in North American nations. According to data from the Breast Cancer Organization, more than 3.8 million American women had been affected by breast cancer as of January 2022.

Key Players 

• Bayer
• Sun Pharmaceutical
• Gilead Sciences
• AstraZeneca
• Eli Lilly
• Pfizer
• Roche
• GlaxoSmithKline
• Novartis
• Merck
• Johnson & Johnson

The market for metastatic breast cancer treatments was USD 17.13 billion in 2021 and will reach $41.74 billion by 2030 at a 10.4% CAGR during the forecast period. Breast cancers are expected to make up about 30% of the newly detected cancer cases in women in 2022, according to breastcancer.org. Additionally, the market is expanding significantly due to extensive R&D efforts to develop effective Breast Cancer Therapeutic Solutions and the rising number of breast cancer patients.